Biotech firm Pulmatrix Q3 loss widens with clinical programs paused

By Reuters News


Overview

  • US biopharma reported Q3 net loss per share of $0.34 as clinical development remains on hold

  • General and administrative expenses rose due to merger-related activities

  • Company expects Eos SENOLYTIX merger to close by year-end, pending final approvals


Outlook

  • Pulmatrix expects merger with Eos SENOLYTIX to close by end of 2026

  • Company says all clinical development is on hold while seeking to license or monetize assets

  • Pulmatrix anticipates cash position sufficient to fund operations through anticipated merger closing


Result Drivers

  • CLINICAL DEVELOPMENT ON HOLD - All clinical programs paused as company seeks to license or monetize assets

  • MERGER-RELATED COSTS - General and administrative expenses rose due to legal and professional services for proposed Eos SENOLYTIX merger


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.34


Reuters Recommended Reads

  • Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 16 - Moleculin Biotech Q3 net loss narrows as MIRACLE trial advances

  • Nov 16 - ALX Oncology Q3 net loss per share narrows


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.